LYON, France , April 25, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale and installation of Ablatherm Robotic HIFU at Houston Methodist Hospital , Houston, Texas . The hospital is the first location in Texas to install
HIFU Resource Center Online at www.urotoday.com EDAP and the Ablatherm-HIFU now have a HIFU section in the most popular urology web site in the world : http://www.urotoday.com . Urotoday.com is a scientific web site serving urologists visited by more than 50,000 urologists every month worldwide.
From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer UroToday.com announced today the addition of Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results
LYON, France , Jan. 25, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Sylvester Comprehensive Cancer Center , Miami , using FDA approved Ablatherm Robotic HIFU.
ENLIGHT Newsletter We are excited that EDAP continues to make substantial progress with our U.S. clinical ENLIGHT trial. In the attached newsletter, please find a message from Cary Robertson, MD, the trial's Primary Investigator and John Rewcastle, PhD, EDAP's Medical Director, outlining the
LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its participation to two major forthcoming international robotics and urology congresses: EAU : European Association of Urology – Amsterdam July 1-4
LYON, France , Oct. 11, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the results of a multicentric study using Ablatherm Robotic HIFU which demonstrates promising oncologic outcomes with low side effects.
